Clinical trials
Completed Cutaneous Squamous Cell Carcinoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Maastricht University Medical Center | 3 |
| National Cancer Institute (NCI) | 3 |
| Regeneron Pharmaceuticals | 3 |
| TuHURA Biosciences, Inc. | 2 |
| CivaTech Oncology | 1 |
| Corporacion Parc Tauli | 1 |
| Dana-Farber Cancer Institute | 1 |
| Incyte Corporation | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Merck Sharp & Dohme LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cutaneous Squamous Cell Carcinoma | 27 |
| Skin Neoplasms | 7 |
| Basal Cell Carcinoma | 6 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Keratosis, Actinic | 3 |
| Carcinoma, Merkel Cell | 2 |
| Carcinoma, Squamous Cell | 2 |
| Carcinoma, Transitional Cell | 2 |
| Head and Neck Neoplasms | 2 |
| Melanoma | 2 |
Trials
Showing 76 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.